Um estudo para investigar a eficácia e a segurança do SAR441566 em pacientes com colite ulcerosa (SPECIFI-UC)
Um estudo de fase 2, multinacional, multicêntrico, randomizado, duplo-cego, controlado por placebo e alcance da dose para avaliar a eficácia e a segurança do SAR441566 em adultos com ulcerativa moderada a grave
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis.
This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment.
Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study).
- The study duration will be up to 59 weeks.
- The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm.
- The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, 10117
- Investigational Site Number : 2760005
-
Berlin, Alemanha, 14050
- Investigational Site Number : 2760008
-
Duisburg, Alemanha, 47055
- Investigational Site Number : 2760010
-
Frankfurt, Alemanha, 60590
- Investigational Site Number : 2760009
-
Hanover, Alemanha, 30625
- Investigational Site Number : 2760003
-
Tübingen, Alemanha, 72076
- Investigational Site Number : 2760011
-
Ulm, Alemanha, 89081
- Investigational Site Number : 2760006
-
-
-
-
-
Buenos Aires, Argentina, 1061
- Investigational Site Number : 0320001
-
Buenos Aires, Argentina, 1006
- Investigational Site Number : 0320003
-
Buenos Aires, Argentina, 1023
- Investigational Site Number : 0320002
-
Buenos Aires, Argentina, 1125
- Investigational Site Number : 0320005
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentina, 4000
- Investigational Site Number : 0320004
-
-
-
-
South Australia
-
Kurralta Park, South Australia, Austrália, 5037
- Investigational Site Number : 0360003
-
-
Victoria
-
Richmond, Victoria, Austrália, 3121
- Investigational Site Number : 0360005
-
-
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90035903
- Hospital de Clinicas de Porto Alegre- Site Number : 0760002
-
Porto Alegre, Rio Grande do Sul, Brasil, 90160-093
- Hospital Ernesto Dornelles- Site Number : 0760003
-
-
-
-
-
Burgas, Bulgária, 8000
- Investigational Site Number : 1000001
-
Rousse, Bulgária, 7002
- Investigational Site Number : 1000003
-
Sofia, Bulgária, 1612
- Investigational Site Number : 1000002
-
-
-
-
-
Ghent, Bélgica, 9000
- Investigational Site Number : 0560002
-
Leuven, Bélgica, 3000
- Investigational Site Number : 0560001
-
-
-
-
Nova Scotia
-
Kentville, Nova Scotia, Canadá, B4N 0A3
- Investigational Site Number : 1240004
-
-
Ontario
-
Ajax, Ontario, Canadá, L1S 7K7
- Investigational Site Number : 1240006
-
Richmond Hill, Ontario, Canadá, L4C 9M7
- Investigational Site Number : 1240005
-
-
Quebec
-
Québec, Quebec, Canadá, G1N 4V3
- Investigational Site Number : 1240001
-
-
-
-
Reg Metropolitana de Santiago
-
Santiago, Reg Metropolitana de Santiago, Chile, 8330034
- Investigational Site Number : 1520003
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500010
- Investigational Site Number : 1520002
-
Santiago, Reg Metropolitana de Santiago, Chile, 8331143
- Investigational Site Number : 1520001
-
-
-
-
-
Guangzhou, China, 510655
- Investigational Site Number : 1560002
-
Hangzhou, China, 310016
- Investigational Site Number : 1560001
-
Huizhou, China, 516001
- Investigational Site Number : 1560003
-
Huizhou, China, 516001
- Investigational Site Number : 1560017
-
Jiazhuang, China, 050000
- Investigational Site Number : 1560004
-
Linhai, China, 317000
- Investigational Site Number : 1560014
-
Luoyang, China, 471003
- Investigational Site Number : 1560008
-
Shanghai, China, 200120
- Investigational Site Number : 1560005
-
Wuhan, China, 430014
- Investigational Site Number : 1560011
-
-
-
-
-
Osijek, Croácia, 31000
- Investigational Site Number : 1910001
-
-
-
-
Arizona
-
Sun City, Arizona, Estados Unidos, 85351
- GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400003
-
-
Connecticut
-
Bristol, Connecticut, Estados Unidos, 06010
- Bristol Hospital- Site Number : 8400017
-
-
Florida
-
Clermont, Florida, Estados Unidos, 34711
- Novum Research- Site Number : 8400018
-
Kissimmee, Florida, Estados Unidos, 34741
- Clinical Research of Osceola- Site Number : 8400012
-
Miami Lakes, Florida, Estados Unidos, 33016
- Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400002
-
Tampa, Florida, Estados Unidos, 33609
- GCP Clinical Research- Site Number : 8400016
-
-
Illinois
-
Glenview, Illinois, Estados Unidos, 60026
- GI Alliance - Glenview- Site Number : 8400005
-
Gurnee, Illinois, Estados Unidos, 60031
- Illinois Gastroenterology Group- Site Number : 8400004
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan Health System - Ann Arbor- Site Number : 8400010
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Icahn School of Medicine at Mount Sinai- Site Number : 8400001
-
Queens Village, New York, Estados Unidos, 11428
- Queens Village Primary Medical Center- Site Number : 8400011
-
-
Ohio
-
Lima, Ohio, Estados Unidos, 45805
- NexGen Research- Site Number : 8400020
-
-
Pennsylvania
-
Uniontown, Pennsylvania, Estados Unidos, 15401
- Frontier Clinical Research - Uniontown- Site Number : 8400006
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29401
- Medical University Of South Carolina - MUSC Health Ashley River Tower - ART- Site Number : 8400008
-
-
Texas
-
Katy, Texas, Estados Unidos, 77494
- Gastro Health & Nutrition- Site Number : 8400007
-
Lubbock, Texas, Estados Unidos, 79424
- SI Research Associates- Site Number : 8400019
-
Southlake, Texas, Estados Unidos, 76092
- Texas Digestive Disease Consultants - Southlake- Site Number : 8400015
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- University of Washington Medical Center- Site Number : 8400014
-
Tacoma, Washington, Estados Unidos, 98405
- Washington Gastroenterology - Tacoma- Site Number : 8400009
-
-
-
-
-
Nice, França, 06202
- Investigational Site Number : 2500003
-
Toulouse, França, 31059
- Investigational Site Number : 2500001
-
Vandœuvre-lès-Nancy, França, 54511
- Investigational Site Number : 2500002
-
-
-
-
-
Tbilisi, Geórgia, 0160
- Investigational Site Number : 2680003
-
Tbilisi, Geórgia, 0144
- Investigational Site Number : 2680002
-
Tbilisi, Geórgia, 0180
- Investigational Site Number : 2680001
-
-
-
-
-
Athens, Grécia, 124 62
- Investigational Site Number : 3000003
-
Athens, Grécia, 106 76
- Investigational Site Number : 3000001
-
Heraklion, Grécia, 711 10
- Investigational Site Number : 3000002
-
-
-
-
-
Budapest, Hungria
- Investigational Site Number : 3480001
-
-
-
-
-
Alessandria, Itália, 15100
- Investigational Site Number : 3800007
-
Palermo, Itália, 90127
- Investigational Site Number : 3800009
-
Pisa, Itália, 56124
- Investigational Site Number : 3800004
-
-
Genova
-
Genoa, Genova, Itália, 16132
- Investigational Site Number : 3800006
-
-
Milano
-
Milan, Milano, Itália, 20132
- Investigational Site Number : 3800002
-
Rozzano, Milano, Itália, 20089
- Investigational Site Number : 3800003
-
-
Napoli
-
Naples, Napoli, Itália, 80131
- Investigational Site Number : 3800008
-
-
Padova
-
Padua, Padova, Itália, 35128
- Investigational Site Number : 3800001
-
-
Roma
-
Rome, Roma, Itália, 00161
- Investigational Site Number : 3800011
-
-
Torino
-
Turin, Torino, Itália, 10126
- Investigational Site Number : 3800010
-
-
-
-
-
Hiroshima, Japão, 734-8530
- Investigational Site Number : 3920012
-
Kagoshima, Japão, 892-0843
- Investigational Site Number : 3920016
-
Niigata, Japão, 950-1104
- Investigational Site Number : 3920001
-
Osaka, Japão, 530-0011
- Investigational Site Number : 3920010
-
Tokyo, Japão, 108-8642
- Investigational Site Number : 3920015
-
-
Chiba
-
Kashiwa, Chiba, Japão, 277-0871
- Investigational Site Number : 3920005
-
-
Hiroshima
-
Kure, Hiroshima, Japão, 737-0811
- Investigational Site Number : 3920014
-
-
Hokkaido
-
Sapporo, Hokkaido, Japão, 004-0041
- Investigational Site Number : 3920003
-
Sapporo, Hokkaido, Japão, 065-0033
- Investigational Site Number : 3920007
-
-
Iwate
-
Yahaba, Iwate, Japão, 028-3695
- Investigational Site Number : 3920009
-
-
Kanagawa
-
Yokohama, Kanagawa, Japão, 220-0041
- Investigational Site Number : 3920013
-
-
Tokyo
-
Bunkyo-Ku, Tokyo, Japão, 113-8510
- Investigational Site Number : 3920002
-
Kodaira, Tokyo, Japão, 187-8510
- Investigational Site Number : 3920011
-
-
Yamanashi
-
Kofu, Yamanashi, Japão, 400-0027
- Investigational Site Number : 3920006
-
-
-
-
Lesser Poland Voivodeship
-
Oświęcim, Lesser Poland Voivodeship, Polônia, 32-600
- Investigational Site Number : 6160008
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polônia, 53-034
- Investigational Site Number : 6160005
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polônia, 03-580
- Investigational Site Number : 6160004
-
Warsaw, Masovian Voivodeship, Polônia, 04-501
- Investigational Site Number : 6160001
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Polônia, 35-055
- Investigational Site Number : 6160002
-
-
-
-
-
Constanța, Romênia, 900673
- Investigational Site Number : 6420001
-
-
-
-
-
Olomouc, Tcheca, 779 00
- Investigational Site Number : 2030001
-
Ostrava, Tcheca, 710 00
- Investigational Site Number : 2030002
-
-
-
-
-
Istanbul, Turquia (Türkiye), 34899
- Investigational Site Number : 7920002
-
Izmir, Turquia (Türkiye), 35100
- Investigational Site Number : 7920003
-
Mersin, Turquia (Türkiye), 33070
- Investigational Site Number : 7920001
-
-
-
-
-
Cape Town, África do Sul, 7405
- Investigational Site Number : 7100002
-
Cape Town, África do Sul, 7708
- Investigational Site Number : 7100001
-
KwaDukuza, África do Sul, 4449
- Investigational Site Number : 7100004
-
Pretoria, África do Sul, 0157
- Investigational Site Number : 7100005
-
Pretoria, África do Sul, 0002
- Investigational Site Number : 7100003
-
-
-
-
-
Salzburg, Áustria, 5020
- Investigational Site Number : 0400002
-
Vienna, Áustria, 1090
- Investigational Site Number : 0400001
-
-
-
-
-
Hyderabad, Índia, 500082
- Investigational Site Number : 3560005
-
Jaipur, Índia, 302001
- Investigational Site Number : 3560003
-
Jaipur, Índia, 302004
- Investigational Site Number : 3560009
-
Kolkata, Índia, 700020
- Investigational Site Number : 3560002
-
Ludhiana, Índia, 141002
- Investigational Site Number : 3560004
-
Secunderabad, Índia, 500003
- Investigational Site Number : 3560007
-
Surat, Índia, 395002
- Investigational Site Number : 3560001
-
Visakhapatnam, Índia, 530040
- Investigational Site Number : 3560010
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
-
Male or female participants aged 18 to 75 years inclusive, at the time of signing the informed consent
-
Participants who have clinical evidence of active UC for ≥3 months before screening and confirmed by endoscopy during the screening period
-
Active moderate-to-severe UC at screening as defined by a modified Mayo Score (mMS) of 5 to 9 (without the Physician global Assessment (PGA), with a minimum rectal bleeding (RB) subscore ≥1, a minimum stool frequency (SF) subscore ≥1, a mMES ≥2 confirmed by central reader, a minimum sum of all subscores of 5, and a disease extent >15 cm from the anal verge
-
Must have received prior treatment for UC (either "a" or "b" below or a combination of both "a" and "b"):
- History of no prior exposure to approved Advanced Therapy (AT), but having inadequate response to, loss of response to or intolerance to standard treatment with any of the following : 5-ASA, thiopurines (eg.6-MP, AZA), MTX, oral or intravenous (IV) corticosteroids or history of corticosteroid dependence (defined an inability to successfully taper corticosteroids without recurrence of UC) OR
- History of inadequate response to, loss of response to or intolerance to treatment with ≥1 approved AT such as a biologic agent (eg. TNF antagonists, anti-integrin other than natalizumab, anti-IL-12/23, anti-IL-23, or a small molecule (such as a JAKi or S1PRm) for UC
-
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Participants with active CD, indeterminate colitis, ischemic colitis, microscopic colitis
- Participants with the following ongoing known complications of UC: fulminant colitis, toxic megacolon, or any other manifestation that might require bowel surgery while enrolled in the study
- Participant with prior colectomy, ostomy or ileoanal pouch, or anticipated colectomy during their participation in the study
- Participants with fecal sample positive for ova or parasites, bacterial pathogens, or positive for Clostridium difficile B toxin in stools
- Participants with active tuberculosis (TB) or a history of incompletely treated active TB or latent TB infection per local guidelines
- Participants with Positive Hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) and/or hepatitis C virus antibody (HCVAb) at the screening visit
- Participants with any other active, chronic or recurrent infection, including recurrent or disseminated herpes zoster or disseminated herpes simplex
- Participants with a known history of human immunodeficiency virus (HIV) infection or positive HIV-1 or HIV-2 serology at screening
- Participants presenting with active malignancies, lymphoproliferative disease, or recurrence of either, within the 5 years before screening
- History of gastro-intestinal dysplasia other than completely removed low grade dysplasia OR presence of colonic mucosal dysplasia or adenomatous colonic polyps not removed during endoscopy by the time of the screening visit.
- If the participant has extensive colitis for ≥8 years or disease limited to left side of colon (ie, distal to splenic flexure) for >10 years, regardless of age, a colonoscopy within 1 year of the screening visit is required to survey for dysplasia. Participants with dysplasia or cancer identified on biopsies will be excluded.
- Female participants who is pregnant, breastfeeding, or is considering becoming pregnant during the study or within 3 months after the last dose of study drug
- Infection(s) requiring treatment with IV anti-infectives within 30 days prior to the screening visit or oral/intramuscular anti-infectives within 14 days prior to the screening visit
- Participants requiring or receiving any parental nutrition and/or exclusive enteral nutrition
- Participants who received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to screening
- Participants who received fecal microbial transplantation within 30 days prior to screening
- Participants who have ever been exposed to natalizumab (Tysabri®) or oral carotegrast methyl (Carogra®)
- Participants who received IV corticosteroids within 14 days prior to screening or during screening period
- Screening laboratory and other analyses show abnormal results.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: SAR441566 dose regimen 1
Participants will receive SAR441566 dose regimen 1 |
Pharmaceutical form: Tablet Route of administration: Oral |
|
Experimental: SAR441566 dose regimen 2
Participants will receive SAR441566 dose regimen 2 |
Pharmaceutical form: Tablet Route of administration: Oral |
|
Experimental: SAR441566 dose regimen 3
Participants will receive SAR441566 dose regimen 3 |
Pharmaceutical form: Tablet Route of administration: Oral |
|
Comparador de Placebo: Placebo
Participants will receive SAR441566-matching placebo |
Pharmaceutical form: Tablet Route of administration: Oral |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of participants achieving clinical remission at Week 12 by modified Mayo Score (mMS)
Prazo: Week 12
|
Clinical remission by modified Mayo score (mMS) is defined as a mMS ≤2 with no subscore >1 (stool frequency [SF] of 0 or 1 with at least a 1-point decrease from baseline, rectal bleeding [RB] of 0 and modified Mayo Endoscopic Subscore [mMES] of 0 or 1 where 1 does not include friability). Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity. |
Week 12
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
O plasma prevê concentrações de SAR441566 em visitas selecionadas
Prazo: Até a semana 52
|
Até a semana 52
|
|
|
Concentrações pós -dose plasmáticas de SAR441566 em visitas selecionadas
Prazo: Até a semana 52
|
Até a semana 52
|
|
|
Número de participantes com qualquer tratamento adverso emergente de tratamento (TEAES) durante o período de tratamento de indução e manutenção
Prazo: Até a semana 52
|
Até a semana 52
|
|
|
Número de participantes com qualquer tratamento adverso emergente de tratamento (TEAES) durante o período de tratamento de rótulo aberto
Prazo: Da semana 12 à semana 52
|
Da semana 12 à semana 52
|
|
|
Proportion of participants achieving clinical response at Week 12 by modified Mayo Score (mMS)
Prazo: Week 12
|
Clinical response by modified Mayo score (mMS) is defined as a decrease from baseline in the mMS of ≥2 points and an improvement of ≥30% from baseline plus a decrease in rectal bleeding (RB) subscore ≥1 or an absolute RB subscore ≤1. Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity. |
Week 12
|
|
Proportion of participants achieving clinical response at Week 12 by full Mayo score (MS)
Prazo: Week 12
|
Clinical response by full Mayo score (MS) is defined as a decrease from baseline in the MS of ≥3 points and an improvement of ≥30% from baseline plus a decrease in rectal bleeding (RB) subscore ≥1 or an absolute RB subscore ≤1. The MS (also referred to as the full Mayo Score) is a composite index designed to measure ulcerative colitis (UC) disease activity and consists of 4 subscores: RB and SF, which are patient-reported subscores, Physician's global assessment (PGA), and endoscopic findings. Individual items are rated 0 to 3, giving the composite score a maximum of 12, with higher scores indicating greater disease severity. |
Week 12
|
|
Proportion of participants achieving clinical remission at Week 12 by full Mayo score (MS)
Prazo: Week 12
|
Clinical remission by full Mayo score (MS) is defined as a MS ≤2 with no score >1. |
Week 12
|
|
Proportion of participants achieving the combination of patient-reported outcome 2 (PRO2) remission and endoscopic remission at Week 12
Prazo: Week 12
|
Patient-reported outcome 2 (PRO2) remission is defined as PRO2 score ≤1 with rectal bleeding (RB) of 0, and endoscopic remission is defined as mMES of 0. PRO2 score is defined as the sum of Mayo SF and RB subscores. |
Week 12
|
|
Proportion of participants achieving endoscopic remission at Week 12
Prazo: Week 12
|
Endoscopic remission is defined as mMES of 0. |
Week 12
|
|
Change from baseline in PRO2 from randomization to Week 12
Prazo: From Baseline to Week 12
|
PRO2 score is defined as the sum of the Mayo SF and RB subscores. |
From Baseline to Week 12
|
|
Proportion of participants achieving endoscopic response at Week 12
Prazo: Week 12
|
Endoscopic response is defined as mMES decrease of at least 1 point. |
Week 12
|
|
Proportion of participants achieving endoscopic improvement at Week 12
Prazo: Week 12
|
Endoscopic improvement is defined as mMES of 0 or 1 where 1 does not include friability. |
Week 12
|
|
Proportion of participants achieving HEMI at Week 12
Prazo: Week 12
|
Histologic endoscopic mucosal improvement (HEMI) is defined by achievement of modified Mayo endoscopic improvement (mMES of 0 or 1 where 1 does not include friability) and histological improvement (original Geboes Score [OGS] ≤3.1). |
Week 12
|
|
Proportion achieving Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 12
Prazo: Week 12
|
Inflammatory Bowel Disease Questionnaire (IBDQ) remission is considered as an IBDQ-32 total score ≥170 points. IBDQ is designed to capture the patient's experience of IBD on 4 domains of functioning and well-being: bowel and systemic symptoms and emotional and social function. The total IBDQ score ranges from 32 to 224 which indicates better quality of life. |
Week 12
|
|
Proportion of participants achieving Inflammatory Bowel Disease Questionnaire (IBDQ) response at Week 12
Prazo: Week 12
|
Inflammatory Bowel Disease Questionnaire (IBDQ) response is defined as an increase from baseline in the total IBDQ score in the range of 16 to 32 points. |
Week 12
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- DRI17822
- U1111-1308-9729 (Outro identificador: WHO)
- 2025-520705-12 (Identificador de registro: CTIS)
- 2025 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .